Canadian medical cannabis patients saw improvements in pain, anxiety, and depression over 6 months, but none reached clinically meaningful thresholds | Research

The takeaway

A 24-week observational study of Canadian medical cannabis patients found statistically significant improvements in pain, anxiety, depression, and quality of life, but no outcome met the threshold for minimal clinically important difference.

Medical cannabis patients, prescribing physicians, health policy researchers

Improvements were statistically significant but fell short of clinically meaningful thresholds

What the researchers found

Over 24 weeks, patients showed improvements in pain interference (-4.6 points), numeric pain rating (-1.19), anxiety (-2.24), depression (-2.79), and quality of life (-0.56). While all changes were statistically significant, none reached their respective minimal clinically significant thresholds. 85% of patients had a primary indication of pain.

Why it matters

This is a rare long-term observational study of physician-authorized medical cannabis with validated outcome measures. The gap between statistical significance and clinical significance raises important questions about how meaningful the improvements actually are for patients.

The numbers in context

Pain interference: -4.6 (CI: -6.02 to -3.17, n = 137); pain rating: -1.19 (CI: -1.7 to -0.68, n = 137); GAD-7 anxiety: -2.24 (CI: -3.5 to -0.99, n = 139); PHQ-9 depression: -2.79 (CI: -4.29 to -1.3, n = 141); QoL: -0.56 (CI: -0.96 to -0.16, n = 139); 85% pain indication

How the study worked

Prospective observational multicenter study from the Canadian Medical Cannabis Real-World Evidence study. Adult patients chose from Health Canada-verified products via a national pharmacy platform with physician guidance. Validated questionnaires (PROMIS, NPRS, GAD-7, PHQ-9, EQ-5D-3L) administered at weeks 0, 6, 12, and 24. Analyzed per-protocol and intention-to-treat.

What this study cannot tell us

No control group or randomization. Small sample sizes at 24 weeks due to dropout. Cannot separate cannabis effects from placebo, natural disease course, or concurrent treatments. Product heterogeneity across patients.

How to read the evidence

Moderate: multicenter prospective design with validated measures and 24-week follow-up, but no control group and small completion sample.

When this study was published

2026 publication from the Canadian Medical Cannabis Real-World Evidence study.

The bigger picture

This finding is nuanced: medical cannabis is associated with measurable improvements, but those improvements may not be large enough to feel meaningfully different to patients. This is a common challenge in pain medicine and warrants honest discussion in the medical cannabis debate.

Questions still open

Would specific products or dosing regimens reach clinically meaningful thresholds? Is the failure to meet clinical thresholds due to patient selection, product variability, or inherent limitations of cannabis? Do patients perceive meaningful benefit despite not meeting clinical thresholds?

Common questions

Did medical cannabis help Canadian patients?

Statistically, yes. Pain, anxiety, depression, and quality of life all improved over 24 weeks. However, the improvements did not reach the thresholds typically considered clinically meaningful, meaning patients may not have experienced a noticeable difference.

What is the difference between statistical and clinical significance?

Statistical significance means a change is unlikely due to chance. Clinical significance means the change is large enough to be noticed by patients. A treatment can be statistically significant without being clinically meaningful.

Read the original research

Canadian real-world evidence: observational 24-week outcomes for health care practitioner authorized cannabis.

Canadian journal of pain = Revue canadienne de la douleur, 10(1), 2593253

View on PubMed ↗Publisher’s paper ↗

Citation

Yang, Brian; Diep, Calvin; Thaker, Sonalben; Jackson, Ted; Lakhani, Aly; Landolt, Carolina; Pope, Elena; Lara-Corrales, Irene; Cortes Pradilla, Henry; Yu, Hai Chuan; Mae Gabriel, Gretchen; Darville, Rasheeda; Weisbrod, Ken; Tingling, Keriann; Nandra, Kiritpaul; Ganty, Praveen; Fiorellino, Joseph; Huang, Alexander; Tao, Leeping; Singh, Mandeep; Chung Tai, Peter; Carlen, Peter; Ladha, Karim; Clarke, Hance. (2026). Canadian real-world evidence: observational 24-week outcomes for health care practitioner authorized cannabis.. Canadian journal of pain = Revue canadienne de la douleur, 10(1), 2593253. https://doi.org/10.1080/24740527.2025.2593253